HDAC2-dependent miRNA signature in acute myeloid leukemia

FEBS Lett. 2019 Sep;593(18):2574-2584. doi: 10.1002/1873-3468.13521. Epub 2019 Jul 19.

Abstract

Acute myeloid leukemia (AML) arises from a complex sequence of biological and finely orchestrated events that are still poorly understood. Increasingly, epigenetic studies are providing exciting findings that may be exploited in promising and personalized cutting-edge therapies. A more appropriate and broader screening of possible players in cancer could identify a master molecular mechanism in AML. Here, we build on our previously published study by evaluating a histone deacetylase (HDAC)2-mediated miRNA regulatory network in U937 leukemic cells. Following a comparative miRNA profiling analysis in genetically and enzymatically HDAC2-downregulated AML cells, we identified miR-96-5p and miR-92a-3p as potential regulators in AML etiopathology by targeting defined genes. Our findings support the potentially beneficial role of alternative physiopathological interventions.

Keywords: HDAC2; SAHA; epigenetics; immunoregulation; leukemia; miRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Gene Regulatory Networks
  • Genes, MHC Class II / genetics
  • Histone Deacetylase 2 / metabolism*
  • Humans
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology*
  • MicroRNAs / genetics*

Substances

  • MicroRNAs
  • HDAC2 protein, human
  • Histone Deacetylase 2